Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds from the Offering are approximately $19 million, before deducting placement a ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of autism focu ...

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental di ...

Core Viewpoint - RetinalGenix Technologies Inc. has partnered with LabCorp to launch a cost-effective DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform aimed at improving early detection of ocular and systemic diseases while reducing reliance on expensive diagnostic procedures [1][6]. Group 1: Collaboration and Methodology - The collaboration allows patients to visit LabCorp locations for genetic testing and high-resolution retinal imaging, utilizing proprietary algorithms to correlate genetic and retinal biomarkers [2][3]. - The methodology aims to establish a new standard for early detection of various health conditions, enhancing accessibility and affordability of healthcare services [5][6]. Group 2: Technological Innovations - RetinalGenix is introducing high-resolution retinal imaging as an additional service, which is expected to improve diagnostic accuracy and facilitate mass screening by general practitioners and standard eye clinics [4][7]. - The integration of genetic screening and advanced imaging technologies is designed to prevent blindness and detect early physiological changes indicative of future diseases [7]. Group 3: Market Impact and Future Prospects - The company is working with regulators to establish CPT codes, which could lower healthcare costs and streamline patient assessment processes [6]. - As the database of disease-associated biomarkers expands, the value of the DNA/RNA/GPS platform for diagnosing diseases is anticipated to grow, promising improved patient outcomes and more accessible care [3][4].

Core Viewpoint - INmune Bio Inc. has announced a registered direct offering of 3,000,000 shares of its common stock at a price of $6.30 per share, aiming to raise approximately $19 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about June 30, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2]. - The offering is made under an effective shelf registration statement previously filed with the SEC [3]. Group 2: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system [5]. - The company has three product platforms: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which is in clinical trials for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [5]. - The Natural Killer Cell Priming Platform, which includes INKmune® for cancer treatment, currently in trials for metastatic castration-resistant prostate cancer [5]. - The CORDStrom™ platform, which recently completed a trial for recessive dystrophic epidermolysis bullosa [5].

Core Insights - Tempus AI (TEM) is experiencing significant growth in its Data and Services segment, with a 43.2% year-over-year revenue increase to $61.9 million in Q1 2025, driven by a 58% growth in its Insights data licensing business [1][7] - The company has secured major contracts, including a $200 million licensing agreement with AstraZeneca (AZN) and Pathos, which has increased AZN's total remaining contract value to over $1 billion [2][7] - Tempus has expanded collaborations with key pharmaceutical companies, including Illumina and Boehringer Ingelheim, enhancing its position in biomarker development and oncology applications [3][7] Financial Performance - Gross profit for Tempus outpaced revenue growth, increasing by 65.2% with only a modest 3% rise in the cost of revenues [1] - Year-to-date, Tempus AI shares have surged 102.5%, significantly outperforming the industry average growth of 18% [6] Competitive Landscape - Competitors like ICON (ICLR) and IQVIA (IQV) are also experiencing growth, but Tempus AI's performance in securing contracts and expanding its service offerings positions it favorably in the market [4][5] - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.47X, compared to the industry average of 5.83X, indicating a premium valuation [8]

Core Insights - Tango Therapeutics has initiated the first patient dosing in a Phase 1/2 trial for TNG462 in combination with Revolution Medicines' daraxonrasib or zoldonrasib targeting MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer [1][2] - The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG462 in combination with the mentioned inhibitors [2] - TNG462 is a promising MTA-cooperative PRMT5 inhibitor, with monotherapy data expected in the second half of 2025, which may inform a registrational trial for pancreatic cancer in 2026 [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision cancer medicines [4] - The company employs the genetic principle of synthetic lethality to create therapies targeting critical cancer-related pathways [4]

Excelitas is a leading provider of advanced, life-enriching technologies that make a difference, serving global market leaders in the life sciences, advanced industrial, next-generation semiconductor and avionics end markets. Headquartered in Pittsburgh, PA, USA, Excelitas is an essential partner in the design, development and manufacture of advanced technologies, offering leading-edge innovation in sensing, detection, imaging, optics and specialty illumination for customers worldwide. Excelitas is at the f ...

ACADIA Pharmaceuticals (ACAD) Update / Briefing June 25, 2025 08:30 AM ET Speaker0 All right. Speaker1 Good morning, everybody, and thank you so much for joining us for Acadia's inaugural R and D Day. Welcome to the people in the room here at our hotel. Welcome to everybody online. We're delighted that you took time today to join us because today marks an exciting milestone for the company as we open the curtain on the innovation engine driving our future. We're here to share meaningful insights into our pi ...

Core Insights - EXACT Therapeutics has initiated its ENACT trial, marking the first patient dosed in a Phase 2 clinical trial for Acoustic Cluster Therapy (ACT) in pancreatic cancer patients [1][2] - The trial aims to address the significant unmet medical need in treating pancreatic cancer, which has over 500,000 new diagnoses globally each year and is known for its high mortality rate [2] - The Phase 2 trial will enroll up to 25 patients across the U.S., U.K., and Europe, following positive results from a Phase 1 trial involving patients with liver metastases of colorectal origin [3] Company Overview - EXACT Therapeutics is a clinical-stage precision medicine company focused on utilizing ultrasound and microbubbles for targeted drug delivery in oncology [4] - The company’s Acoustic Cluster Therapy (ACT) represents a novel approach that may be applicable to various therapeutic agents in oncology and other medical indications, including brain diseases [4] - Shares of EXACT Therapeutics are traded on Euronext Growth Oslo under the ticker EXTX [4]